A House bill aimed at getting more generic drugs on the market won’t be moving on a fast track to markup.
The legislation (H.R. 749) is intended to lower drug prices by introducing more generic drug competition. Drugmakers are under heavy scrutiny by lawmakers, consumers, medical professionals and the president for their pricing practices.
The measure was introduced Jan. 30 by Reps. Gus Bilirakis (R- Fla.) and Kurt Schrader (D-Ore.). The sponsors and House Energy and Commerce Committee staff are working on a bipartisan basis to revise the bill before it is considered by the committee, a committee aide told me March 6.
Among other things, the bill would require the Food and Drug Administration to prioritize and act on generic applications within 180 days of being filed for drug products that are in short supply or when there are too few manufacturers on the market.
“There are a group of drugs where there’s not a lot of competition where this could help expedite the review process if FDA would be able to meet that 180-day time clock,” David Rosen, an attorney with Foley & Lardner LLP in Washington, told me. Rosen is the chair of the firm’s FDA regulatory practice and was employed at the FDA for 14 years.
However, some, including the head of the FDA’s drug center, don’t think a 180-day review period is possible.
Janet Woodcock, the director of the Center for Drug Evaluation and Research, said March 2 that the FDA can’t get too much quicker than an eight-month review, because the agency needs time to inspect the facilities where these products are made and some of the facilities are in foreign countries.
Woodcock spoke during a House Energy and Commerce Health Subcommittee hearing on the bill and the FDA's generic drug and biosimilar user fee programs.
Read my full article here.
Stay on top of new developments in health law and regulation with a free trial to the Health Law Resource Center.
Learn more about Bloomberg Law and sign up for a free trial.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)